$CAMP

Young Richard A purchased $27K of CAMP

Young Richard A purchased 16,378 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.

Original reporting
SEC EDGAR · Young Richard A
Published Aug 5, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CAMP
Bullish
medium confidence
Mentioned
$CAMP
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAMPBullishLow
01

Why it matters

The only new fact is the director’s open-market purchase details (shares, price, total value, and post-transaction holdings). No operational updates, guidance, or regulatory/clinical catalysts are included.

02

Market read

Traders may note the insider buy as a small sentiment input, but it does not introduce new fundamental information.

03

What to watch

The filing does not state motivations, and there is no 10b5-1 plan involvement; without additional context, the signal may be weak.

Relevance 4/10Novelty 3/10Timing: Form 4 filed Aug. 5, covering an Aug. 3 purchase.

Background

This is an SEC Form 4 insider transaction disclosure for Camp4 Therapeutics, reported by a director.

Company-level read

Ticker impact

$CAMPBullishMedium confidence
Context

Director Young Richard bought 16,378 shares of Camp4 Therapeutics at $1.65/share for about $27.0K, disclosed via Form 4 filed Aug. 5.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider buys can influence short-term sentiment, but the transaction size ($27K) is small relative to typical market-moving thresholds and provides no new operating or guidance information.

Market effects

No clear sector read-through from a single small insider purchase.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine liquidity or diversification activity and do not necessarily imply improved near-term prospects.

Key entities

  • Camp4 Therapeutics Corp

    Subject of the Form 4 insider transaction disclosure.

  • Young Richard

    Director who reported the open-market purchase.

Related articles